Editorial Videos

Fred Aslan, MD, CEO, Artiva Biotherapeutics, explains what the FDA Fast Track designation for AlloNK in autoimmune diseases means for the acceleration of its development and potential approval of the therapy.

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses Lynparza’s role in reducing the risk of invasive disease recurrence or death in HR-positive breast cancer patients.

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses the concept of an immune reset and what the company is tracking in trials to assess its potential.

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how key regulatory designations, such as the FDA's Regenerative Medicine Advanced Therapy designation, facilitate accelerated development and commercialization of DB-OTO through increased collaboration with regulators.

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses two ongoing trials for autoimmunity indications in the US and how AlloNK differs from traditional B-cell depletion strategies.

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses the promising results of DB-OTO in the CHORD trial for children with otoferlin-related hearing loss.

Dr. Hernan Bazan, CEO of South Rampart Pharma, discusses his company’s current pipeline.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, describes how his company's recent partnership with Pfizer is impacting drug access.

Dr. Hernan Bazan, CEO of South Rampart Pharma, discusses his company’s current pipeline.

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses how results of the trial compare with other treatments for gBRCAm HER2-negative high-risk early breast cancer.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, explores how tariffs could affect the availability and accessibility of specific medications, particularly for patients relying on direct-to-patient telehealth.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, discusses why pharma increasingly turning to peer-to-patient platforms to educate patients, as well as relationships with trusted patient communities and pharmacies.

Ron Lanton, Partner, Lanton Law, discusses the legal and industry challenges posed by recent National Institute of Health budget cuts, diversity bans in clinical trials, and pharmaceutical supply chain disruptions due to tariffs.

In this part of his Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, identifies strategies that pharmaceutical companies and digital health platforms can employ to navigate a potential drop in demand due to tariff-induced increased costs.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, the role pharma should be playing in helping to ensure patients have access to health insights they can trust.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, addresses how tariffs will affect pharmaceutical costs and which drug categories will be most affected.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, shares some best practices on finding trustworthy and verified information about a new prescription or medical device.

Daniel Vitt, CEO, Immunic Therapeutics, discusses how the company is positioning itself to lead in the area of gastrointestinal diseases.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, talks about where patients are turning for trustworthy health information and some strategies that can be used to verify information.

Daniel Vitt, CEO, Immunic Therapeutics, discusses how the safety and tolerabilities results from Phase I trials for IMU-856 influences further studies for gastrointestinal diseases moving forward.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer of Pleio, discusses the significant threat of misinformation to public health and how emotional appeal plays a part.

John Arena, interim president of global pharma services at Cencora, discusses how new technologies are shortening timelines.

John Arena, interim president of global pharma services at Cencora, discusses the importance of engaging with partners as early as possible during development in order to achieve a smooth product launch.

John Arena, interim president of global pharma services at Cencora, discusses how companies must prepare for each market and its unique regulatory requirements.

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about how collaborations, like the one with Celltrion, have been instrumental in the company's success.

James Foster, CEO and co-founder of Virax Biolabs, discusses how global launches are being impacted by changing geopolitical conditions.

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about how the recent NASDAQ listing will aid in accelerating R&D and commercialization efforts.

John Arena, interim president of global pharma services at Cencora, discusses how companies can continue to develop launch strategies while taking potential regulatory changes into consideration.